Overview

MInimal Residual Disease Adapted Strategy

Status:
Not yet recruiting

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard vs high-risk cytogenetics defined by the LP score including 17p deletion, t(4;14), del(1p32), gain 1q, trisomy 21 and trisomy 5).

Phase:

Phase 3

Details

Lead Sponsor:

Intergroupe Francophone du Myelome

Collaborators:

Amgen
Bristol-Myers Squibb
Sanofi

Treatments:

Lenalidomide